Biovica International Ab Class B · OMXSTO:BIOVIC_B
Biovica International Ab Class B — Stora Aktiedagen i Lund (January 2019)
22 slides from Biovica International Ab Class B's conference presentation, Jan 29, 2019
Slide 1: Best possible treatment from day 1
Best possible treatment from day 1 January 2019 1
Slide 2: Biovica develops and commercializes blood based assays
Biovica develops and commercializes blood based assays for prognosis and monitoring of effect of targeted cancer treatments Our objective is to enable best possible treatment for cancer patients from day one! Anders Rylander CEO 2
Slide 3: Biovica in Brief
Biovica in Brief • Develops biomarker assays for enabling personalized treatments for better outcome • Biotech company in early commercial phase • Listed on First North • Market Cap ~ SEK 160 m • Annual turnover of SEK 2.7 m • Patented technology 3
Slide 4: Why invest in Biovica?
Why invest in Biovica? • Beneficial for cancer patients and payers • Addresses an unmet need for personalized treatments within metastatic cancer • Large market potential of SEK 6 billion for metastatic breast cancer area in US & Europe • Strong scientific collaborations and evidence • Early commerc
Slide 5: The product DiviTum®
The product DiviTum® • Measures cell proliferation • Implemented on standard platform • Strong competitive position 5
Slide 6: DiviTum® a blood based biomarker assay
DiviTum® a blood based biomarker assay • Blood based • Monitor and predict treatment response in cancer therapy • ELISA – standardized platform • CE-marked • Patented method and kit 6
Slide 7: DiviTum® provides early response to whether or not the patient's cancer treatment is effective
DiviTum® provides early response to whether or not the patient's cancer treatment is effective Image DiviTum ® diagnostics Months DiviTum® measures cell proliferation rate for faster evaluation of cancer treatment effects References: See http://biovica.com/technology/publications/ 7
Slide 8: DiviTum® - strong position in regards to competing / complementary technologies
DiviTum® - strong position in regards to competing / complementary technologies Imaging • Standard method for treatment evaluation • Requires 3-4 months follow up time • Example: PET/CT, MRI Biopsies • Tumor samples collected through a needle • Invasive, not suitable for treatment monitoring • Examp
Slide 9: Unmet need and market
Unmet need and market • First application – metastatic breast cancer (MBC) • Potential of SEK 6 billion/year in US and Europe alone (MBC) • Long term potential – standard marker for cancer treatment evaluation 9
Slide 10: There's an unmet need for biomarkers for individualized cancer treatments
There’s an unmet need for biomarkers for individualized cancer treatments • Many treatment options • Efficacy evaluation • Treatment resistance • Cost issues • Time consuming diagnostics 10
Slide 11: Cost for cancer treatments exceeds USD 100 billion!
Cost for cancer treatments exceeds USD 100 billion! ≥ 90% of new treatments are targeted or hormonals – Biovica focus area Oncology Therapeutics (BUSD) Oncology Development Pipeline (# of new compounds) 120 700 100 600 500 80 400 60 300 40 200 20 100 0 0 2013 2014 2015 2016 2017 2005 2006 2007 2008
Slide 12: Biovica focuses primarily on metastatic breast cancer
Biovica focuses primarily on metastatic breast cancer Breast cancer • 450 000 patients with metastatic breast cancer in US and Europe Lung cancer • Market potential SEK 6 billion/year (US GI-cancer & Europe) • Additional potential: Research market, other metastatic cancers, local cancer, CDx, etc Ot
Slide 13: Strong Clinical Study Results for DiviTum®
Strong Clinical Study Results for DiviTum® • 16 articles, peer reviewed and published in oncology journals • Results within major oncology areas (Breast, Lung, Gastro Intestinal, Blood malignancies) • Ongoing program within breast cancer with world leading cancer institutes 13
Slide 14: DiviTum® - Strong evidence within breast cancer
DiviTum® - Strong evidence within breast cancer Screening Early Breast Cancer Locally Advanced disease Metastatic disease High Risk Stage I-II Stage III Stage IV BRCA Early Breast Cancer, TEX Metastatic Breast Cancer, Chemo therapy, 287 pat 80 pat 161 pat Breast Cancer Targeted Therapy US, Metastati
Slide 15: DiviTum® summary of results from published breast cancer studies
DiviTum® summary of results from published breast cancer studies, all with statistically significant results Study Stage #Pat Results DiviTum able to predict which high-risk-patients (BRCA-positive) that would BRCA High risk 80 develop cancer. BC early I,II 161 DiviTum able to predict risk for recur
Slide 16: Ongoing metastatic breast cancer study program in collaboration with world-leading institutes
Ongoing metastatic breast cancer study program in collaboration with world-leading institutes Study Stage #Pat Endpoints Status PYTHIA IV 120 TK-activity for targeted drug response 2019 PREDIX III 200 TK for targeted drug response and survival 2020 FELINE III 120 TK for targeted drug response and co
Slide 17: Road to market
Road to market • Early commercial phase • 4 main work flows • Clinical development • Product development • Regulatory approval • Market access • Next milestone: FDA application 17
Slide 18: Biovica go-to market plan
Biovica go-to market plan 2013 2015 2017 2019 2021 Clin 1st MBC 1st targeted MBC MBC Regulatory & Demand Dev Targeted Lung & GI Pilot Prod DiviTum CE DiviTum FDA Dev FDA Pre-sub Supp.#1 Supp.#2 Reg. Dev CE FDA Sales research market Mar- ket Commercial partnerships Acc. Reimbursement 18
Slide 19: Team
Team • Experience of taking biomarker assays and oncology products to market • Experience of FDA and reimbursement processes • Committed, a majority of key people are Biovica shareholders 19
Slide 20: Experienced management team
Experienced management team Anders Rylander CEO Holdings: 3 575 640 A-shares and 360 956 B-shares Pontus Nobreus Adam Germunder Cecilia Driving Business Dev. Director Operations Director CFO Holdings: 6 000 B-shares Holdings: 3 600 B-shares and Holdings: 9 000 B-shares 20 000 warrants 20 000 warrant
Slide 21: Board of Directors
Board of Directors Göran Brorsson Chairman Holdings: 73 245 A-shares, 116 000 B-shares, 3 000 warrants Maria Holmlund Jarl Ulf Jungnelius Board Member Board Member Holdings: 9 750 B-shares Holdings: 0 Jesper Söderqvist Anders Rylander Board Member Board Member Holdings: 41 085 A-shares, Holdings: 3
Slide 22: Best possible treatment from day 1
Best possible treatment from day 1 January 2019 22
Biovica International — Stora Aktiedagen i Lund (January 2019) on 6ix